Company logo

Orexo | Sustainability Performance

https://orexo.com

Orexo AB is engaged in the development of pharmaceuticals, particularly in the field of addiction treatment and pain management, with a focus on distinct drug delivery technologies.

1995

Sweden

51 - 200 employees

Pharmaceuticals

$25M - 100M in revenue

N/A in profitability

Sustainability Ranking & Industry Benchmark

#7190
Overall
#372
in Sweden
#170
in Pharmaceuticals

Sustainability Maturity


Sustainability Intent

Available in
Scale package

Access

Industry Rank

160 out of 287

Overview
Environmental
Energy consumption
Governance
Targets
Financial Data
Business performanceCapital & innovationAnalyst projections
Renewable energy Proportion of the company's total electricity consumption sourced from renewable sources, expressed as a percentage.
95%2022
Aligned
Revenue Total revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
26.0M$, 202511.5% YoY
R&D intensity Research and development expenditure expressed as a percentage of revenue, reflecting the company's relative investment in innovation.
896.15%2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Orexo's opioid dependence treatment products operate in a pharmaceutical segment with inherent controversy around addiction treatment approaches.
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

image report
Available

Sustainability employees

We follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

Total sustainability employees

2-3

This value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.


    Available in
    Scale package

    Access